Edgewise Therapeutics, Inc. cash flow to debt ratio of -3.60K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Edgewise Therapeutics, Inc.'s free cash flow has decreased 30.34% from $-110.34M last year to $-143.82M, signaling decreasing performance

Edgewise Therapeutics, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.

Edgewise Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.01 last year to 0.01 today, signaling strengthened financials

Edgewise Therapeutics, Inc. has a net cash position, so leverage is healthy.

Edgewise Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Edgewise Therapeutics, Inc. has insufficient data to evaluate this check.

Edgewise Therapeutics, Inc.'s short-term assets of $543.38M exceed its short-term liabilities of $27.37M

Edgewise Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Edgewise Therapeutics, Inc.'s return on equity of -39.01%, is lower than 15.00%, indicating bad performance

Edgewise Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Edgewise Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Edgewise Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Edgewise Therapeutics, Inc. has negative free cash flow, indicating cash burn

Edgewise Therapeutics, Inc.'s yearly earnings has decreased 25.40% since last year from $-133.81M to $-167.79M, signaling decreasing performance

Edgewise Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -48.46% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Edgewise Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Edgewise Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Edgewise Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Edgewise Therapeutics, Inc. has insufficient data to evaluate this check.

Edgewise Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Edgewise Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Edgewise Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Edgewise Therapeutics, Inc. has insufficient data to evaluate this check.

Edgewise Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Edgewise Therapeutics, Inc. has a price-to-book ratio of 10.71x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Edgewise Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue